Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
64.93
+2.13 (3.39%)
At close: Oct 31, 2025, 4:00 PM EDT
64.01
-0.92 (-1.42%)
After-hours: Oct 31, 2025, 7:53 PM EDT
Nektar Therapeutics Employees
Nektar Therapeutics had 61 employees as of December 31, 2024. The number of employees decreased by 76 or -55.47% compared to the previous year.
Employees
61
Change (1Y)
-76
Growth (1Y)
-55.47%
Revenue / Employee
$1,228,426
Profits / Employee
-$2,004,443
Market Cap
1.23B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61 | -76 | -55.47% |
| Dec 31, 2023 | 137 | -79 | -36.57% |
| Dec 31, 2022 | 216 | -524 | -70.81% |
| Dec 31, 2021 | 740 | 22 | 3.06% |
| Dec 31, 2020 | 718 | -5 | -0.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NKTR News
- 2 days ago - Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - PRNewsWire
- 4 days ago - Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets - PRNewsWire
- 5 days ago - San Francisco is making a comeback. So are these stocks from the City by the Bay - CNBC
- 11 days ago - Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting - PRNewsWire
- 6 weeks ago - Why Is Nektar Therapeutics Stock Trading Lower On Thursday? - Benzinga
- 6 weeks ago - Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 - PRNewsWire
- 7 weeks ago - Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 - PRNewsWire
- 2 months ago - What's Going On With Nektar Therapeutics Stock On Thursday? - Benzinga